Overview

This trial is active, not recruiting.

Condition hepatitis c
Treatments intervention group, control group
Sponsor Shanghai Mental Health Center
Start date July 2011
End date May 2015
Trial size 340 participants
Trial identifier NCT01647191, JDu-001

Summary

The proposed study will investigate the knowledge level, attitudes, and perceptions among staff of Methadone Maintenance Treatment (MMT) clinics and intravenous drug users (IDUs) who attending MMT clinics, which is the most reachable population for HCV/HIV intervention in China. This study will also explore the barriers that prevent IDUs from getting HCV/HIV intervention/prevention and medical care services. This study will help to understand and address this important problem in China and other Asian countries.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking open label
Primary purpose prevention
Arm
(Experimental)
The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
intervention group some types intervention activities for this group
The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
(Active Comparator)
The investigators will adopt previous treatment in the clinics to intervent the patients without any type of target intervention for this group.
control group without any type of target intervention for this group
The investigators will adopt previous treatment in the clinics to intervent the patients

Primary Outcomes

Measure
Knowledge、Risk Behaviors and some other aspects related to HCV/HIV will be measured among IDUs in MMT
time frame: 3 months

Secondary Outcomes

Measure
The barriers will be measured.
time frame: 3 months
The ways will be measured.
time frame: 3 months

Eligibility Criteria

Male or female participants at least 20 years old.

Inclusion Criteria: - several failed attempts to quit the use of heroin - at least two terms in a detoxification center - age at least 20 years - being a registered local resident of the area in which the clinic is located - being of good civil character Exclusion Criteria: - there is no exclusion criteria

Additional Information

Official title Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China
Principal investigator Jiang Du, M.D
Description The investigators propose to conduct 3 inter-related studies over 4 years using both qualitative and quantitative research methods to address a series of research questions. Firstly, The investigators will begin by assessing HCV/HIV knowledge, attitudes, perceptions, risk behaviors, and infection among IDUs in MMT clinics (Study 1) and HCV/HIV knowledge, attitudes, and HCV/HIV-related services among MMT staff (Study 2). Secondly, based on knowledge accumulated from Studies 1 & 2; The investigators will adapt and develop HCV/HIV education materials appropriate for Chinese IDUs and drug treatment service providers, and then use the Transtheoretical Model of Behavior Change as a conceptual model to measure if our educational program will increase patients' readiness to consider changing HCV/HIV risk behaviors and getting medical care for HCV/HIV (Study 3). Finally, by integrating findings of these three studies and by consulting with leading experts in HCV/HIV. The investigators plan to develop HCV/HIV intervention program applicable in China, which can be tested in future formal experimental trials.
Trial information was received from ClinicalTrials.gov and was last updated in July 2012.
Information provided to ClinicalTrials.gov by Shanghai Mental Health Center.